Literature DB >> 24050854

Invasive renal cell carcinoma with inferior vena cava tumor thrombus: cardiac anesthesia in liver transplant settings.

Kyota Fukazawa1, Edward Gologorsky2, Kirstin Naguit3, Ernesto A Pretto1, Tomas A Salerno4, Mohan Arianayagam5, Richard Silverman1, Michael E Barron1, Gaetano Ciancio4.   

Abstract

OBJECTIVES: Resection of renal cell carcinomas (RCC) with tumor thrombus invasion into the inferior vena cava (IVC) is associated with significant perioperative morbidity and mortality. This study examined the intra- and inter-departmental collaboration among cardiac, liver transplantation, and urologic surgeons and anesthesiologists in caring for these patients.
DESIGN: After IRB approval, medical records of patients who underwent resection of RCC tumor thrombus level III and IV, from 1997 to 2010 in this institution, were reviewed. Data were collected and analyzed by one way-ANOVA and chi-square test.
SETTING: Major academic institution, tertiary referral center. PARTICIPANTS: This was a retrospective study based on the medical records of patients who underwent resection of RCC tumor thrombus level III and IV, from 1997 to 2010.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Fifty-eight patients (82.9%) with level III thrombus and 12 patients (17.1%) with level IV thrombus were analyzed. Sixty-five (92.9%) did not require any extracorporeal circulatory support; 5 (2 with level III and 3 with level IV; 7.1%) required cardiopulmonary bypass. No patients required veno-venous bypass. Compared to patients with level III thrombus extension, patients with level IV had higher estimated blood loss (6978±2968 mL v 1540±206, p<0.001) and hospital stays (18.8±1.6 days v 8.1±0.7, p<0.001). Intraoperative transesophageal echocardiography (TEE) was utilized in 77.6% of patients with level III thrombus extension and in 100% of patients with level IV thrombus extension. Intraoperative TEE guidance resulted in a significant surgical plan modification in 3 cases (5.2%). Short-term mortality was low (n = 3, 4.3%).
CONCLUSIONS: Utilization of specialized liver transplantation and cardiac surgical techniques in the resection of RCC with extension into the IVC calls for a close intra-and interdepartmental collaboration between surgeons and anesthesiologists. The transabdominal approach to suprahepatic segments of the IVC allowed avoidance of extracorporeal circulatory support in most of these patients. Perioperative management of these patients reflected the critical importance of TEE-proficient practitioners experienced in liver transplantation and cardiac anesthesia.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac anesthesia; invasion of inferior vena cava; liver transplant; renal cell carcinoma; transesophageal echocardiography

Mesh:

Year:  2013        PMID: 24050854     DOI: 10.1053/j.jvca.2013.04.002

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  4 in total

1.  Transesophageal echocardiography-guided thrombectomy of intracardiac renal cell carcinoma without cardiopulmonary bypass.

Authors:  Fouad Ghazi Souki; Michael Demos; Lilibeth Fermin; Gaetano Ciancio
Journal:  Ann Card Anaesth       Date:  2016 Oct-Dec

2.  Transesophageal Echocardiography-Guided Thrombectomy of Level IV Renal Cell Carcinoma without Cardiopulmonary Bypass.

Authors:  Petar Zlatanovic; Igor Koncar; Nenad Jakovljevic; Dejan Markovic; Aleksandar Mitrovic; Lazar Davidovic
Journal:  Braz J Cardiovasc Surg       Date:  2019 Mar-Apr

3.  Anesthetic management of one-stage scheduled surgery for adrenal cortical carcinoma complicated by massive pulmonary tumor embolism.

Authors:  Kazuma Yunoki; Tsutomu Wada; Ikuko Miyawaki; Kazuo Yamazaki; Hiroyuki Mima
Journal:  JA Clin Rep       Date:  2017-09-02

4.  Surgical Management of Upper Urinary Tract Urothelial Cell Carcinoma with Venous Tumor Thrombus: A Liver Transplant-Based Approach.

Authors:  Gaetano Ciancio; Marina M Tabbara; Melanie Martucci; Jeffrey J Gaynor; Mahmoud Morsi; Javier Gonzalez
Journal:  J Clin Med       Date:  2021-12-19       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.